Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Resmed has completed its acquisition of Noctrix Health, making it a wholly owned subsidiary and expanding its clinical sleep health portfolio into Restless Legs Syndrome (RLS). The deal brings Noctrix’s Nidra® TOMAC Therapy, an FDA De Novo classified non-pharmacologic treatment for moderate-to-severe RLS, into Resmed’s ecosystem of connected devices and digital health solutions.
Key figures
- Rls prevalence
- ~8% of adults
- Peer reviewed publications
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.